scholarly journals Incidence, risk factors, and dose-volume relationship of radiation-induced rib fracture after carbon ion radiotherapy for lung cancer

2015 ◽  
Vol 55 (2) ◽  
pp. 163-166 ◽  
Author(s):  
Takanori Abe ◽  
Katsuyuki Shirai ◽  
Jun-Ichi Saitoh ◽  
Takeshi Ebara ◽  
Hirofumi Shimada ◽  
...  
2014 ◽  
Vol 9 (1) ◽  
pp. 92 ◽  
Author(s):  
Go Sasahara ◽  
Masashi Koto ◽  
Hiroaki Ikawa ◽  
Azusa Hasegawa ◽  
Ryo Takagi ◽  
...  

2012 ◽  
Vol 52 (3) ◽  
pp. 538-544 ◽  
Author(s):  
Ayae Kanemoto ◽  
Masashi Mizumoto ◽  
Toshiyuki Okumura ◽  
Hideto Takahashi ◽  
Takayuki Hashimoto ◽  
...  

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3229
Author(s):  
Takashi Ono ◽  
Naoyoshi Yamamoto ◽  
Akihiro Nomoto ◽  
Mio Nakajima ◽  
Yuma Iwai ◽  
...  

There are no studies on the risk factors of radiation pneumonitis (RP) after carbon-ion radiotherapy at a dose of 50 Gy (relative biological effectiveness (RBE)) in a single fraction. The objective of this study was to identify factors associated with RP after radiotherapy, including dose–volume parameters. Ninety-eight patients without a history of thoracic radiotherapy who underwent treatment for solitary lung tumors between July 2013 and April 2016 were retrospectively analyzed. Treatment was planned using Xio-N. The median follow-up duration was 53 months, and the median clinical target volume was 32.3 mL. Three patients developed grade 2 RP, and one patient developed grade 3 interstitial pneumonitis. None of the patients developed grade 4 or 5 RP. The dose-volume parameters of the normal lung irradiated at least with 5–30 Gy (RBE), and the mean lung dose was significantly lower in patients with grade 0–1 RP than in those with grade 2–3 RP. Pretreatment with higher SP-D and interstitial pneumonitis were significant factors for the occurrence of symptomatic RP. The present study showed a certain standard for single-fraction carbon-ion radiotherapy that does not increase the risk of RP; however, further validation studies are needed.


2013 ◽  
Vol 2013 ◽  
pp. 1-6 ◽  
Author(s):  
Naoyoshi Yamamoto ◽  
Mio Nakajima ◽  
Hirohiko Tsujii ◽  
Tadashi Kamada

The clinical results after carbon ion radiotherapy for the metastatic lung tumors believed to be in the state of oligo-recurrence were evaluated. One hundred and sixteen lesions in 91 patients with lung cancer metastasis were treated with carbon ion radiotherapy at our institute from April 1997 to February 2011. Regarding the prescribed dose, total dose ranged between 40 gray equivalents (GyE) and 80 GyE, and fraction size ranged from 1 to 16 fractions. After a median followup period of 2.3 years (range, 0.3–13.1 years), the statistical overall survival rate and local control rate were 71.2% and 91.9% at 2 years after treatment, respectively. Treatment-related side effects were not a clinical problem. When classified by the primary organ, there were 49 cases of lung cancer, 20 cases of colorectal cancer, and 22 cases of others. The overall survival rate and local control rate for lung metastasis cases from lung cancer at 2 years after treatment were 81.5% and 92.4%, respectively, and 65.0% and 92.0% regarding lung metastasis from colorectal cancer. Carbon ion beam therapy for the metastatic lung tumors is a safe therapy, and the therapeutic effect is comparable to the outcome obtained from reported surgical resections.


Sign in / Sign up

Export Citation Format

Share Document